Deerfield launches protein degradation start-up Neomorph with $109M series A

Neomorph emerged from stealth Tuesday with a $109 million series A round from founding investor Deerfield to advanced its targeted protein degradation platform and pipeline.

Deerfield Management co-founded Neomorph Inc. this year with scientific founders Phil Chamberlin, who serves as the company’s president and CSO; Eric Fisher, an associate professor of biological chemistry and molecular pharmacology at Harvard Medical School and an investigator at Dana-Farber Cancer Institute; Benjamin Ebert, a professor of medicine at Harvard and chair of the medical oncology department at Dana-Farber; and Scott Armstrong, a professor of pediatrics at Harvard and Dana-Farber. ...